Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Kim Young-Jin, a director at Rezolute , Inc. (NASDAQ:RZLT), has recently acquired a substantial number of shares in the company. According to a recent SEC filing, Kim purchased 1,250,000 common shares at $4.00 per share, amounting to a total investment of $5 million. The purchase represents a significant stake in the $275 million market cap company, which has seen its stock surge over 213% in the past year. According to InvestingPro analysis, analysts have set price targets ranging from $9 to $16.
This acquisition increases the shares held indirectly by Handok, Inc., a company with which Kim is affiliated. Additionally, Kim received 25,500 restricted stock units, which will vest fully on March 1, 2026. Furthermore, Kim acquired options to purchase 15,000 shares, set to vest on the same date.
These transactions highlight Kim’s continued confidence in Rezolute’s prospects, as he expands his stake in the pharmaceutical firm.
In other recent news, Rezolute has shared its second quarter fiscal year 2025 financial results, revealing a strong cash position of approximately $105 million. The company is advancing its Phase 3 sunRIZE study, which evaluates the drug candidate ersodetug for treating congenital hyperinsulinism. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ersodetug, aiming to expedite its development due to promising results from earlier trials. Analysts from JMP Securities have increased their price target for Rezolute to $9, maintaining a Market Outperform rating, while H.C. Wainwright reiterated a Buy rating with a $14 target. Both firms highlighted the importance of the ongoing Phase 3 trials and the potential of ersodetug. The Data Monitoring Committee has approved the enrollment of infants in the sunRIZE trial, confirming the drug’s safety at the tested doses. Rezolute plans to complete patient enrollment by the second quarter of 2025, with topline results expected by the end of the year, although a delay to mid-2026 is possible if increased enrollment is required. The company has also released a video presentation providing insights into their Phase 2 clinical trial, emphasizing the importance of patient perspectives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.